Short‐term or long‐term treatments with a phosphodiesterase‐4 (PDE4) inhibitor result in opposing agonist‐induced Ca2+ responses in endothelial cells
Open Access
- 1 May 2008
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 154 (1), 82-92
- https://doi.org/10.1038/bjp.2008.56
Abstract
Background and purpose: We previously reported that agonist‐induced rises in cytoplasmic Ca2+ concentration ([Ca2+]i) in human umbilical vein endothelial cells (HUVEC) were inhibited after a short‐term (2 min) pre‐treatment with cAMP‐elevating agents. The aim of this work was to study the effects of longer term (8 h) pre‐treatment with dibutyryl‐cAMP (db‐cAMP) or rolipram, a specific inhibitor of phosphodiesterase‐4 (PDE4), on [Ca2+]i, cAMP levels and PDE activity and expression in HUVEC. Experimental approach: [Ca2+]i changes were measured in isolated HUVEC by Fura‐2 imaging. Intracellular cAMP levels and PDE4 activity were assessed by enzyme‐immunoassay and radio‐enzymatic assay, respectively. PDE expression was measured by northern and western blot analysis. Key results: Long‐term pre‐treatment of HUVEC with rolipram or db‐cAMP significantly increased ATP‐, histamine‐ and thrombin‐induced [Ca2+]i rises. Short‐term pre‐treatment with rolipram was associated with an increase in cAMP, whereas long‐term pre‐treatment was associated with a decrease in cAMP. Long‐term pre‐treatment with rolipram or db‐cAMP induced a significant increase in PDE4 activity and the expression of 74 kDa‐PDE4A and 73 kDa‐PDE4B was specifically enhanced. All these effects were suppressed by cycloheximide. Conclusions and implications: Our data suggest that sustained inhibition of PDE4 by rolipram induced an increase in PDE4 activity, possibly as a compensatory mechanism to accelerate cAMP degradation and that PDE4A and PDE4B were implicated in the regulation of [Ca2+]i. Thus, isozyme‐specific PDE4 inhibitors might be useful as therapeutic agents in diseases where [Ca2+]i handling is altered, such as atherosclerosis, hypertension and tolerance to β‐adrenoceptor agonists.Keywords
This publication has 63 references indexed in Scilit:
- AMPK and transcriptional regulationFrontiers in Bioscience-Landmark, 2008
- Modulation of VEGF-induced endothelial cell cycle protein expression through cyclic AMP hydrolysis by PDE2 and PDE4Thrombosis and Haemostasis, 2004
- VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitorsThrombosis and Haemostasis, 2003
- Synergistic Effects of Highly Unsaturated Fatty Acid-containing Phosphatidyl-ethanolamine on Differentiation of Human Leukemia HL-60 Cells by Dibutyryl Cyclic Adenosine MonophosphateJapanese Journal of Cancer Research, 2001
- α2A-Adrenergic Receptor Stimulation Potentiates Calcium Release in Platelets by Modulating cAMP LevelsPublished by Elsevier BV ,2000
- Regulation of Ca2+release by cAMP-dependent protein kinase A mechanism for agonist-specific calcium signaling?Cell Calcium, 1999
- Modulation of spasmogen‐stimulated Ins(1,4,5)P3 generation and functional responses by selective inhibitors of types 3 and 4 phosphodiesterase in airways smooth muscleBritish Journal of Pharmacology, 1998
- Indomethacin enhances endothelial NO release — evidence for a role of PGI2 in the autocrine control of calcium-dependent autacoid productionCardiovascular Research, 1997
- Amplitude modulation of Ca2+ signals induced by histamine in human endothelial cellsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1994
- Tissue and substrate specificity of inhibition by alkoxy-aryl-lactams of platelet and arterial smooth muscle cyclic nucleotide phosphodiesterases relationship to pharmacological activityBiochemical and Biophysical Research Communications, 1983